Valuation: Fluicell AB

Market Cap 41.21M 4.35M 3.76M 3.51M 3.22M 6.06M 414M 6.16M 16.18M 207M 16.33M 15.97M 686M P/E 2024
-1.1x
P/E 2025 -1.65x
Enterprise Value 38.95M 4.11M 3.55M 3.32M 3.05M 5.73M 391M 5.82M 15.29M 196M 15.43M 15.1M 648M EV / Sales 2024
0.71x
EV / Sales 2025 0.75x
Free-Float
75.27%
Yield 2024 *
-
Yield 2025 -
1 day-0.66%
1 week-3.54%
Current month-3.54%
1 month-12.79%
3 months-10.18%
6 months+217.46%
Current year+200.00%
1 week 29.2
Extreme 29.2
31.8
1 month 27.6
Extreme 27.6
37
Current year 7.65
Extreme 7.65
67.2
1 year 7.65
Extreme 7.65
67.2
3 years 7.45
Extreme 7.45
594.3
5 years 7.45
Extreme 7.45
12,145
10 years 7.45
Extreme 7.45
15,330
Manager TitleAgeSince
Chief Executive Officer 42 01/01/2023
Chief Tech/Sci/R&D Officer 46 01/01/2017
Director of Finance/CFO 56 01/07/2023
Director TitleAgeSince
Director/Board Member 54 01/01/2017
Director/Board Member 51 01/01/2017
Director/Board Member 62 01/01/2015
Change 5-day change 1-year change 3-year change Capi.($)
-0.66%-3.54%+175.23%-94.00% 4.35M
+0.99%+1.78%+5.07%+16.49% 49.47B
+3.71%+9.40%+486.14%+579.98% 43.97B
+5.60%+10.21%+20.85%+81.78% 39.6B
+2.70%+1.57%+32.71%+9.07% 39.29B
+2.21%+6.75%+20.20%+54.40% 32.43B
+2.23%+4.71% - - 16.84B
+0.97%+2.35%+35.99%+124.45% 16.49B
-0.11%+2.41%+5.03%+20.47% 14.01B
+0.75%+15.04%+79.84%+29.70% 12.77B
Average +1.84%+5.33%+95.67%+91.37% 26.49B
Weighted average by Cap. +2.54%+6.10%+105.14%+138.67%

Financials

2024 2025
Net sales 5.35M 564K 488K 456K 418K 787K 53.72M 799K 2.1M 26.92M 2.12M 2.07M 89.01M 15.22M 1.61M 1.39M 1.3M 1.19M 2.24M 153M 2.27M 5.97M 76.61M 6.03M 5.9M 253M
Net income -15.51M -1.64M -1.42M -1.32M -1.21M -2.28M -156M -2.32M -6.09M -78.07M -6.15M -6.01M -258M -8.33M -879K -760K -710K -651K -1.23M -83.67M -1.24M -3.27M -41.94M -3.3M -3.23M -139M
Net Debt -15.92M -1.68M -1.45M -1.36M -1.25M -2.34M -160M -2.38M -6.25M -80.15M -6.31M -6.17M -265M -2.26M -239K -206K -193K -177K -333K -22.72M -338K -888K -11.39M -896K -877K -37.64M
Logo Fluicell AB
Fluicell AB is a Sweden-based company within healthcare industry. It commercializes a product portfolio for processing and studying of individual cells, primarily in the field of drug development. The Company’s products comprise research tools BioPen and Dynaflow Resolve. Tools enable researchers to study, process and measure drug impact on individual cells. Also, the Company develops bioprinting technology Biopixlar Retina in both two-dimensional (2D) and three-dimensional (3D) options. Biopixlar Retina creates complex tissue-like structures with control over positioning of individual cells.
Employees
11
Date Price Change Volume
07/08/26 SEK 30.00 -0.66% 5,023
06/08/26 SEK 30.20 -0.98% 1,957
05/08/26 SEK 30.50 +3.39% 4,261
04/08/26 SEK 29.50 -3.28% 3,936
03/08/26 SEK 30.50 -1.93% 1,378
  1. Stock Market
  2. Stocks
  3. FLUI Stock